InnoPharmax Selected for Poster Presentation on“ A Novel Controlled-release Formulation of Carvedilol” and “Rapid-acting Oral Insulin Formulation” at 2015 CRS Annual Meeting & Exposition
Taipe, Taiwan, R.O.C.--2015 CRS annual meeting will be held in Edinburgh, Scotland from July 26th through July 29th. InnoPharmax Inc. announced that the Company's R&D product on “ A Novel Controlled-release Formulation of Carvedilol” and “Development of Rapid-acting Oral Insulin Formulation” has been accepted for poster presentation.
l About Development of Rapid-acting Oral Insulin Formulation：
A rapid-acting oral insulin formulation was developed using nanoemulsion solutions containing unmodified insulin (regular insulin). Rapid-acting insulin oral formulation begins to produce its effect within 15 minutes of oral administration, and peak levels occur at 30 minutes. Duration of activity is less than three hours. In addition, glucodynamic responses of oral insulin formulation presents proportional to the dose administrated.
l About A Novel Controlled-release Formulation of Carvedilol：
A novel controlled-release formulation of Carvedilol (INNO-C08001) is developed to extend the duration of drug release. INNO-C08001 is also designed to maintain an adequate plasma concentration to reduce fluctuation of blood pressure as well as to reduce drug administration frequency from twice a day (BID) to once daily (QD). It has been successfully demonstrated comparative bioavailability and pharmacokinetic profile to Dilatrend® tablet in the previous clinical study.
l About InnoPharmax
InnoPharmax is a specialty pharmaceutical company focused in the development and commercialization of products for the treatment of infectious diseases, immunology and oncology. It develops and acquires potential drug candidates for further development as well as commercialization, and uses internally developed drug delivery technology platforms for improving the safety and effectiveness of currently available drugs to provide better medical choices in these specific disease categories. Contact e-mail：business@innopharmax.com
2015 CRS Annual Meeting & Exposition
Date：July 26th－July 29th, 2015
Venue:：Edinburgh, Scotland
Poster topics and numbers：
l A Novel Controlled-release Formulation of Carvedilol (Poster Number: 270 in Poster Session I)
l Development of Rapid-acting Oral Insulin Formulation (Poster Number: 302 in Poster Session I)
Contact e-mail：business@innopharmax.com
